ClinicalTrials.gg
CompletedNCT06367322StarkUpdated Apr 16, 2024

Statins and Post-ERCP Acute Pancreatitis (Stark Project)

An observational study in Post-ERCP Acute Pancreatitis, sponsored by Hospital General Universitario de Alicante. Completed at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Hospital General Universitario de Alicante · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,016
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Pancreatitis with a site in Spain — 5 open to participants now, 5 under way, 1 of them phase 3. Pancreatitis · Spain.

Started
2017
with 3 others
Observational
8 of 21
1 open now
Registered
19th of 21
by date
Lead sponsor
3 of 21
Hospital General Universitario de Alicante

Among the 21 studies in Pancreatitis with a site in Spain, this one is one of 4 that started in 2017, is one of 8 observational ones, and was the 19th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

5 of the 21 studies in Pancreatitis with a site in Spain are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Pancreatitis with a site in Spain, or all of them as a file.
02

Study summary

Post-endoscopic retrograde cholangiopancrepatography (ERCP) acute pancreatitis (PEAP) is a frequent complication of this endoscopic procedure. Chronic statin intake has been linked to lower incidence and severity of acute pancreatitis (AP). Periprocedural rectal administration of non-steroidal anti-inflammatory drugs is protective against PEP, but the role of chronic acetylsalicylic acid (ASA) treatment is unclear. The aim of the study is to investigate whether statins and chronic ASA intake are associated with lower risk of PEAP.

Read the detailed description

Introduction:

Acute Pancreatitis (AP) is the most frequent complication after ERCP; its incidence is around 3.5-4.5%. Post-ERCP AP (PEAP) is defined as a clinical pancreatitis (new or worsened abdominal pain) with amylase/lipase at least three times the upper limit of normal at more than 24 hours after the procedure, requiring hospital admission or a prolongation of planned admission. It is resulting in increased morbidity of patients undergoing this technique, and an increased in health spending, due to prolonged hospital days and patient needs. In this context, different strategies have been investigated to prevent PEAP, for example rectal NSAIDs (indomethacin or diclofenac 100 mg just before or after procedure) and pancreatic stents.

On the other hand, statins are widely used drugs aimed to lower cholesterol blood levels (the frequency of statin use, may be as high as 50% of men and 36% of women between the ages of 65 years and 74 years in USA). The relationship between statins and AP has been controversial. In the past, it was believed that statins were associated to an increased risk of AP. In Data Sheet of different International Drug Agencies, we can find their mainly indications (hypercholesterolemia, mixed dyslipidaemias, hereditary hypercholesterolemia) and commons adverse effects with reference to acute pancreatitis (myopathy, rhabdomyolysis, hepatitis/jaundice, acute pancreatitis...). Besides, some studies, most of them case series or case reports, have associated the use of different statins with drugs induced AP.

However, recent evidence suggests the opposite: Statins could reduce the risk of AP. In a retrospective longitudinal cohort study on data from a big health database from California (USA), with a big population of three millions nine thousand people, the incidence of AP among subjects who used simvastatin was significantly lower than who didn´t use it (0,80 (0,80-0,81)/100.000 consumers/day versus 1,28 (1,27-1,28) /100.000 no consumers/day; crude incidence rate ratio for risk of AP with simvastatin use 0.626 (95% confidence interval (CI) 0.588-0.668, p\<0.0001). In this study patients who received simvastatin were more likely to have gallstone-related disorders, alcohol dependence or hyper-triglyceridemia compared with the reference population; nevertheless, risk of AP was significantly reduced with simvastatin use. In multivariate analysis, simvastatin was independently associated with reduced risk of pancreatitis, adjusted RR 0.29 (95%CI 0.27-0.31) after adjusting for age, gender, race/ethnicity, gallstone disorders, alcohol dependence, smoking and hypertriglyceridemia. Similar results were noted with atorvastatin. In a Meta-analysis of 21 randomized controlled trials investigating effects of lipid-modifying therapies on cardiovascular events, was assessed the relationship between lipid modifying therapies and risk of AP. In this study it was concluded that the use of statin therapies was associated with a lower risk of AP, RR 0.79 (95%CI 0.65-0.95; p=0.01). In a case-control study from Denmark, it was examined if statins use is associated with increase risk of acute pancreatitis. 2576 first-time admitted cases of AP were controlled with 25 817 gender-matched controls from the general population. Prescriptions for statins prior to admission with acute pancreatitis or index date among controls were retrieved from prescription databases. Its findings speak against a strong causative effect of statins on the risk of acute pancreatitis, and speculated about it could indicate a mild protective effect.

Some studies even speculate about an improvement in the severity of AP among patients with prior use of statins. In a prospective cohort study from Croatia, which included patients with acute pancreatitis divided into two groups according to statin use prior to hospitalization, severe disease was more common in the no-statin group than in statin group (20.6% vs. 8.7% p=0.001), and severity markers were also higher in the no-statin group.

It isn´t clear what is the mechanism by which statins might have a beneficial effect on acute pancreatitis. Basic studies suggest that statins could act on a specific anti-inflammatory pathway, inhibited them, as hypothesize experimental models. Statin effect that may be relevant to AP include blockade of the interleukin 6 mediated Janus kinase/signal transducer pathway and up regulation of the unfolded protein response helpful in modulating the endoplasmic reticulum stress response.

Based on the above evidence, the study hypothesis is that statins consumption is associated to a decreased incidence of PEAP. A prospective cohort study is proposed, focused on patients undergoing ERCP, with the aim to compare the incidence of PEAP among patients consuming statins and those who do not.

Material and Methods:

Hypothesis: Statins consumption decreases incidence of PEAP. I. Main aim: Compare the incidence of PEAP among patients consuming statins and those who do not.

II. Secondary aims:

  • Investigate the effect of other drugs, especially acetylsalicylic acid (ASA), in the incidence of PEAP.
  • Study the statin mechanism to decrease the incidence of AP.
  • Study the relationship between use of statins and the severity of AP.

Design Study: International multicentric cohort study (observational, analytical, prospective), focused on patients undergoing ERCP, with the aim to compare the incidence of PEAP among patients consuming statins (any statin) and those who do not.

Data acquisition:

Data were prospectively acquired by researchers from the participating centers. After informed consent, the patients were interviewed before and immediately after ERCP. According to local clinical practice, most of the patients were admitted for 24 hours after the procedure to monitor for possible post-ERCP complications, including PEAP. Patients discharged earlier were instructed to return in case of concerning symptoms (persistent abdominal pain, nausea, vomiting, fever, gastrointestinal bleeding etc.). Names and identification data of the patients were not recorded on the electronic case report form in order to ensure confidentiality in accordance with data protection laws. Data monitoring was performed by one of the collaborators. Demographic and analytical data, comorbidities, treatments received (more specifically statins and ASA), pancreatic diseases, procedure results and post-procedural complications were collected.

Sample calculation:

The sample size calculation was based on a presumed 5% incidence of PEAP among non-statin users, an expected 1:3 ratio of statin users to non-users, and a 70% decrease of PEAP rate among statin users. The alpha-error was set to 0.05 and beta-error was set to 0.20. A sample of 1016 patients was accordingly calculated.

Statistical analysis:

The results are expressed as the mean (standard deviation: SD), median (interquartile range: IQR), or n (%). Normality was assessed by means of the Shapiro-Wilk test. For bivariate analysis, quantitative variables were compared with qualitative variables by means of the Student t-test and Mann-Whitney U-test for 2 categories or with ANOVA/Kruskal-Wallis tests for more than 2 categories. Qualitative variables were compared with the chi-square test or Fisher's exact test if needed. Multivariate analysis was performed by means of binary logistic regression. Incidence, odds ratio (OR), and adjusted OR (aOR) were used as measures of the frequency and strength of association, and 95% confidence intervals (CIs) were calculated for OR and aOR. Both OR (95% CI) and aOR (95% CI) were calculated by means of binary logistic regression (bivariate and multivariate analysis, respectively). The multivariate model included those variables that reached statistical significance in the bivariate analysis (p \< 0.05), those variables considered as definite risk factors of PEAP according to the 2014 ESGE guidelines [1], and the prophylactic measures such as periprocedural rectal administration of diclofenac or indomethacin or placement of a pancreatic stent. All statistical tests were 2-tailed, and p-values of less than 0.05 were considered statistically significant.

03

Conditions studied

  • Post-ERCP Acute Pancreatitis

Browse trials for

Keywords

  • Endoscopic retrograde cholangiopancreatography
  • Hydroxymethylglutaryl-Coenzyme A reductase inhibitors
  • Statin
  • Salicylates
  • Acute Pancreatitis
  • Prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from seven tertiary centers in five European countries (Spain, Italy, Croatia, Finland, and Sweden), consecutively undergoing ERCP according to medical indication, over 18 years old, were prospectively recruited and investigated on their demographic characteristics, comorbidities, consumption of statins and other drugs, outcome of the endoscopic procedure and development of post-procedure complications (specifically PEAP).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years old scheduled for ERCP and willing to participate were included.

Exclusion criteria

Exclusion Criteria:

  • Patients with ongoing AP
  • Surgically altered biliary anatomy (such as hepatico-jejunostomy or choledoco-duodenostomy)
  • Failure to reach the papilla
  • Patients undergoing ERCP for stent removal or exchange
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,016 participants (actual)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Statin users

    Patients ≥ 18 years old scheduled for ERCP according to a medical indication, and willing to participate were included, who were receiving treatment with statins. Excluded: patients with ongoing AP, surgically altered biliary anatomy (such as hepatico-jejunostomy or choledoco-duodenostomy), or failure to reach the papilla as well as patients undergoing ERCP for stent removal or exchange were excluded.

    Drug: Statin

  • Non-statin users

    Patients ≥ 18 years old scheduled for ERCP according to a medical indication, and willing to participate were included, who were not receiving treatment with statins. Excluded: patients with ongoing AP, surgically altered biliary anatomy (such as hepatico-jejunostomy or choledoco-duodenostomy), or failure to reach the papilla as well as patients undergoing ERCP for stent removal or exchange were excluded.

Interventions

  • DrugStatinsStudies of StatinsStatins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The primary objective of this study was to determine whether the use of statin has a protective effect against PEAP. Patients undergoing ERCP for a specific medical indication were prospectively reviewed and the incidence of PEAP was compared according to whether or not the patients were receiving statin therapy.

06

What researchers measure

Primary outcomes

  1. To assess the incidence and relative risk of PEAP according to statin use.

    The primary outcome was to compare the incidence and relative risk of PEAP between users of statins and non-users of statins. Subgroup analysis included type of statin and dosing and the consumption of statins the night before the procedure.

    Time frame: 2 years

Secondary outcomes

  1. To assess the effect of chronic use of other drugs on the incidence and relative risk of PEAP.

    The secondary outcome was to investigate the effect of chronic use of other drugs, particularly ASA, on the incidence and relative risk of PEAP.

    Time frame: 2 years

  2. To assess the effect of other factors (demographic and endoscopic) on the incidence and relative risk of PEAP and severity of PEAP (severity according to the Revised Atlanta Classification).

    Other secondary outcome was to investigate the effect of other factors \[body mass index (kg/m2), age (years), active smoking (yes/not), active alcoholism (yes/not), suspected Oddi's dysfunction (yes/not), female sex (yes/not), previous PA (yes/not), duration of cannulation attempts \> 10 minutes (yes/not), pancreatic guide passages \> 1 (yes/not), pancreatic injection (yes/not), and prophylactic endoscopic measures such as periprocedural rectal administration of diclofenac or indomethacin or placement of a pancreatic stent (yes/not)\] on the incidence of PEAP, and the association between the use of statins and ASA and the severity of PEAP.

    Time frame: 2 years

07

Study locations

2 sites
  • Alicante
    Alicante, 03010, Spain
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
08

References and documents

Publications

  • Dumonceau JM, Andriulli A, Elmunzer BJ, Mariani A, Meister T, Deviere J, Marek T, Baron TH, Hassan C, Testoni PA, Kapral C; European Society of Gastrointestinal Endoscopy. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014. Endoscopy. 2014 Sep;46(9):799-815. doi: 10.1055/s-0034-1377875. Epub 2014 Aug 22. PubMed 25148137 ↗
  • Wu BU, Pandol SJ, Liu IL. Simvastatin is associated with reduced risk of acute pancreatitis: findings from a regional integrated healthcare system. Gut. 2015 Jan;64(1):133-8. doi: 10.1136/gutjnl-2013-306564. Epub 2014 Apr 17. PubMed 24742713 ↗
  • Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D. Acute pancreatitis due to pravastatin therapy. JOP. 2003 May;4(3):129-32. PubMed 12743419 ↗
  • Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, LaRosa JC, DeMicco DA, Colhoun HM, Goldenberg I, Murphy MJ, MacDonald TM, Pedersen TR, Keech AC, Ridker PM, Kjekshus J, Sattar N, McMurray JJ. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA. 2012 Aug 22;308(8):804-11. doi: 10.1001/jama.2012.8439. PubMed 22910758 ↗
  • Thisted H, Jacobsen J, Munk EM, Norgaard B, Friis S, McLaughlin JK, Sorensen HT, Johnsen SP. Statins and the risk of acute pancreatitis: a population-based case-control study. Aliment Pharmacol Ther. 2006 Jan 1;23(1):185-90. doi: 10.1111/j.1365-2036.2006.02728.x. PubMed 16393296 ↗
  • Gornik I, Gasparovic V, Gubarev Vrdoljak N, Haxiu A, Vucelic B. Prior statin therapy is associated with milder course and better outcome in acute pancreatitis--a cohort study. Pancreatology. 2013 May-Jun;13(3):196-200. doi: 10.1016/j.pan.2013.03.008. Epub 2013 Mar 14. PubMed 23719587 ↗
  • Wei L, Yamamoto M, Harada M, Otsuki M. Treatment with pravastatin attenuates progression of chronic pancreatitis in rat. Lab Invest. 2011 Jun;91(6):872-84. doi: 10.1038/labinvest.2011.41. Epub 2011 Mar 7. PubMed 21383674 ↗
  • Almeida JL, Sampietre SN, Mendonca Coelho AM, Trindade Molan NA, Machado MC, Monteiro da Cunha JE, Jukemura J. Statin pretreatment in experimental acute pancreatitis. JOP. 2008 Jul 10;9(4):431-9. PubMed 18648134 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jul 2018, 18 months.

Of 82 non-industry observational studies under Pancreatitis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 133. This study's 18 months is below that.

Counting every sponsor, half of 86 studies reached it within 50 months; a quarter within 21 and three quarters within 133.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2024
First posted
Apr 16, 2024
StartActual
Jan 10, 2017
Primary completionActual
Jul 31, 2018
CompletionActual
Sep 30, 2018
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06367322
Lead sponsor
Hospital General Universitario de Alicante
Collaborators
European Pancreatic Club (EPC), Pancreas 2000 Educational Program
Responsible party
Enrique de-Madaria (MD, PhD. Associate Professor of Miguel Hernández University. Research Deputy Director of Alicante Institute for Health and Biomedical Research (acronyms in Spanish: ISABIAL)., Hospital General Universitario de Alicante) — Principal investigator
First posted
Apr 16, 2024
Start date
Jan 10, 2017
Primary completion
Jul 31, 2018
Completion
Sep 30, 2018
Last update
Apr 16, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion